MX2020007326A - Regimen de dosificacion de siponimod. - Google Patents

Regimen de dosificacion de siponimod.

Info

Publication number
MX2020007326A
MX2020007326A MX2020007326A MX2020007326A MX2020007326A MX 2020007326 A MX2020007326 A MX 2020007326A MX 2020007326 A MX2020007326 A MX 2020007326A MX 2020007326 A MX2020007326 A MX 2020007326A MX 2020007326 A MX2020007326 A MX 2020007326A
Authority
MX
Mexico
Prior art keywords
siponimod
dosing regimen
ich
crystals
stroke
Prior art date
Application number
MX2020007326A
Other languages
English (en)
Inventor
Eric Legangneux
Anne Gardin
Erik Wallström
Jang- Ho Cha
Iii Carl Joseph Malanga
Kasra Shakeri-Nejad
Christian Wolf
Frank Dahlke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020007326A publication Critical patent/MX2020007326A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un nuevo régimen de dosificación para la administración de siponimod o cocristales o sales farmacéuticamente aceptables del mismo, en el tratamiento del accidente cerebrovascular, en particular una hemorragia intracerebral (HIC).
MX2020007326A 2017-09-29 2018-09-27 Regimen de dosificacion de siponimod. MX2020007326A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565269P 2017-09-29 2017-09-29
PCT/IB2018/057493 WO2019064217A1 (en) 2017-09-29 2018-09-27 DOSAGE DIAGRAM OF SIPONIMOD

Publications (1)

Publication Number Publication Date
MX2020007326A true MX2020007326A (es) 2020-09-07

Family

ID=63878729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007326A MX2020007326A (es) 2017-09-29 2018-09-27 Regimen de dosificacion de siponimod.

Country Status (11)

Country Link
US (1) US20200306222A1 (es)
EP (1) EP3687531A1 (es)
JP (1) JP2020535139A (es)
KR (1) KR20200062240A (es)
CN (1) CN111132677A (es)
AU (1) AU2018343239A1 (es)
CA (1) CA3074416A1 (es)
IL (1) IL273382A (es)
MX (1) MX2020007326A (es)
RU (1) RU2020114751A (es)
WO (1) WO2019064217A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972954A1 (en) * 2019-05-21 2022-03-30 Synthon B.V. Siponimod maleic acid and fumaric acid salt
CN116456977A (zh) * 2020-09-25 2023-07-18 斯索恩有限公司 西尼莫德盐和共晶
CN112402610A (zh) * 2020-11-20 2021-02-26 睿阜隆(杭州)生物医药有限公司 1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
AU2009327405A1 (en) 2008-12-18 2011-06-30 Novartis Ag New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
RU2011129229A (ru) 2008-12-18 2013-01-27 Новартис Аг Новые соли
HRP20131106T1 (hr) 2008-12-18 2013-12-20 Novartis Ag Hemifumaratna sol od 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
MX367667B (es) * 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
SG191286A1 (en) 2011-01-07 2013-07-31 Novartis Ag Immunosuppressant formulations
WO2013113915A1 (en) 2012-02-03 2013-08-08 Novartis Ag Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
CN106456552A (zh) * 2014-04-10 2017-02-22 诺华股份有限公司 S1p调节剂的立即释放剂量方案
KR102466348B1 (ko) 2014-04-10 2022-11-10 노파르티스 아게 면역억제제 제제

Also Published As

Publication number Publication date
RU2020114751A (ru) 2021-10-29
EP3687531A1 (en) 2020-08-05
KR20200062240A (ko) 2020-06-03
WO2019064217A1 (en) 2019-04-04
US20200306222A1 (en) 2020-10-01
CA3074416A1 (en) 2019-04-04
IL273382A (en) 2020-05-31
CN111132677A (zh) 2020-05-08
JP2020535139A (ja) 2020-12-03
AU2018343239A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
PH12018500894A1 (en) Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab
PH12017502266B1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
MX2017010858A (es) Composicion para el tratamiento de enfermedades relacionadas con la interleucina 6.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MY189913A (en) Preparation containing tetracyclic compound at high dose
MX2020007268A (es) Regimen de dosificacion de siponimod.
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
WO2016089886A3 (en) Methods for treating dry eye disease by administering an il-6r antagonist
PH12018501237A1 (en) Isoindole compounds
MX2016010872A (es) Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.
IN2013MU00711A (es)
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
MX2019010367A (es) Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1).
EA201691741A1 (ru) Фармацевтическая композиция
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
TN2018000326A1 (en) Granule formulation for oral administration.
MX2020007270A (es) Formulacion parenteral que comprende siponimod.
TN2016000497A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.